<DOC>
	<DOCNO>NCT00816348</DOCNO>
	<brief_summary>This compassionate use protocol use intravenous fish oil infusion , Omegaven® , infants child parenteral nutrition-associated liver disease enable reversal elevate serum liver enzyme direct bilirubin ( cholestasis ) .</brief_summary>
	<brief_title>Compassionate Use Omegaven IV Fat Emulsion</brief_title>
	<detailed_description>Intravenous lipid necessary PN ( parenteral nutrition ) dependent patient due high caloric value essential fatty acid content . However , parenteral fat emulsion compose soybean oil ( omega 6 fatty acid ) implicate predispose patient PN associate liver disease . It hypothesize administer Omegaven® , comprise fish oil ( omega 3 fatty acid ) place conventional soybean fat emulsion , progression PN-associated cholestasis may prevent reverse .</detailed_description>
	<mesh_term>Cholestasis</mesh_term>
	<criteria>Two consecutive direct bilirubin level 2 mg/dl parenteral nutrition dependent infant child ( unable meet nutritional need solely enteral nutrition ) Other cause liver disease exclude . A liver biopsy necessary treatment . The patient must utilize standard therapy prevent progression liver disease include reduction/removal copper manganese daily PN , trial enteral feeding possible , use ursodiol ( i.e. , Actigall® ) . Documented cause chronic liver disease parenteral nutrition associate liver disease Proven severe advance liver disease include cirrhosis biopsy , varix , ascites . An allergy seafood product , egg protein , and/or previous allergy Omegaven® Active coagulopathy characterize ongoing bleeding requirement clot factor replacement ( e.g . fresh frozen plasma cryoprecipitate ) maintain homeostasis Impaired lipid metabolism severe hyperlipidemia without pancreatitis Unstable diabetes mellitus hyperglycemia Stroke , embolism , collapse shock , recent MI Cholestasis due reason parenteral associate liver disease Active new infection time initiation Omegaven® Hemodynamic instability The patient may enrol clinical trial involve investigational agent ( unless approve designated physician multidisciplinary team ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cholestasis</keyword>
	<keyword>Parenteral Nutrition Associated Liver Disease</keyword>
</DOC>